


Gate Opening Summit for Innovative Drug Discovery

資 上	料野	2		_ 裕	ì	1 明	;	0 様
Dо	сu	m	е	n	t	2 -	1	0

Be a Leading Country in Global Drug Discovery

July 30, 2024 Japan Pharmaceutical Manufacturers Association Hiroaki Ueno, Ph.D.





The key is to continue movements toward strengthening the drug discovery eco-system as national strategy

Pharmaceutical Industry Initiatives to Strengthen Drug Discovery Eco-system



Industry group

Each company

Common initiatives to promote drug discovery activities

Open innovation activities based on each company's strategies

Initiatives by JPMA

Collaboration in non-competitive areas for sustainable innovation creation

- Industry-academia-government collaboration
- Provide an industrial perspective
- Human resources development

Industry-academia consortium leveraging the strengths of academia research, etc.

A mechanism to provide knowledge to academic researchers (AMED-FLuX), etc.



ENT For biostatistics, biopharmaceutical manufacturing (BCRET), etc.

Recommendations and proposals towards government industrial policies


- Drug pricing, pharmaceutical affairs
- Drug discovery capabilities, industrial policy

FY 2024 Drug Price Revision, the Pharmaceutical Affairs Committee^{*1}, etc.

The drug discovery capability concept meeting^{*2}, headquarters for healthcare policy, etc.

夏 製薬協

Constructive and deep discussions from the following perspectives in order to strengthen global drug discovery capabilities in Japan



JPMA will contribute the discussion in "the Public-Private Council"